Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis (Review Article)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Zhao Liming; LIU YING; Cao Ziting; WANG JUN; Huo Xin

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Public Health Year:2023 | Volume:52 | Issue:5 Page(s): 903-912

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis (Review Article)

Author(s)

Keywords

Cardiovascular risk

Adverse events

Proprotein convertase 9

Alirocumab

Evolocumab

Abstract

Background: Proprotein convertase subtilisin / Kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents. This drug is related to improving the prognosis of patients with cardiovascular disease (CVD). The pur-pose of this meta-analysis was to systematically analyze the safety and efficacy of PCSK9 inhibitors in all pub-lished randomized controlled trials (RCTs). Methods: As of October 25, 2021, we searched PubMed, EMBASE, MEDLINE, Cochrane Library and web of science. Results: From 684 articles, we included 11 trials for meta-analysis, including 52511 participants (26938 in the PCSK9 inhibitor group and 25573 in the control group). In terms of effectiveness, PCSK9 inhibitors reduced the risk of major adverse cardiovascular events(MACE) (OR=0. 89, 95% Cl: 0. 83-0. 95, P=0. 0009), but did not significantly reduce the risk of cardiovascular death (OR=0. 95, 95% Cl: 0. 84-1. 07, P=0. 38) or all-cause death (OR=0. 93, 95% Cl: 0. 85-1. 03, P=0. 18),In terms of safety, PCSK9 did not increase the risk of treatment-emergent Adverse events (TEAE)(OR=0. 98, 95% Cl: 0. 94-1. 02, P=0. 28). Conclusion: PCSK9 inhibitors can significantly reduce the risk of MACE in patients with high Cardiovascular risk, which is well tolerated, but the impact on the risk of death is unclear.

Cites

No record.

References

Cite

APA: Copy

Zhao, Liming, LIU, YING, Cao, Ziting, WANG, JUN, & Huo, Xin. (2023). Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis (Review Article). IRANIAN JOURNAL OF PUBLIC HEALTH, 52(5), 903-912. SID. https://sid.ir/paper/1098204/en

Vancouver: Copy

Zhao Liming, LIU YING, Cao Ziting, WANG JUN, Huo Xin. Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis (Review Article). IRANIAN JOURNAL OF PUBLIC HEALTH[Internet]. 2023;52(5):903-912. Available from: https://sid.ir/paper/1098204/en

IEEE: Copy

Liming Zhao, YING LIU, Ziting Cao, JUN WANG, and Xin Huo, “Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis (Review Article),” IRANIAN JOURNAL OF PUBLIC HEALTH, vol. 52, no. 5, pp. 903–912, 2023, [Online]. Available: https://sid.ir/paper/1098204/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops